Stock Analysis
West Pharmaceutical Services, Inc.WST
P/E 47.84×· 5Y range 25.20–66.74×· 72th percentile of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsStrong Buy23 analystsP/E 47.8× sits at the 72nd percentile of its 5.089664613278576-year history.
Cash covers 390% of debt · FY 2025.
PMP Verdict
High quality, fairly valued
Strengths
- Financial Health100
- Quality82
Risks
- Growth26
Strong fundamentals at a reasonable valuation.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 18.3 — safe-zone balance sheet
- ✓ROE 17.8% — efficient capital deployment
- ✓Interest coverage 108.0× — debt well covered
What's happening with WST
Profile
Strong financial health, earnings quality, moat and profitability; growth and valuation lag behind.
How is each axis scored?
- Valuation27/100 · Weak
- P/E vs own history (72th pct)5/25
- FCF yield (1.6%)5/25
- P/S (8.1x)12/25
- EV/EBIT (38.9x)5/25
- Growth26/100 · Weak
- Revenue CAGR (2.1%)6/25
- Net income CAGR (-7.1%)0/25
- EPS CAGR 5Y (-5.9%)0/25
- Fwd implied growth (25.2%)20/25
- Profitability80/100 · Strong
- ROIC (20.8%)20/25
- ROE (17.8%)20/25
- Net margin (17.0%)20/25
- Operating margin (20.5%)20/25
- Financial Health100/100 · Strong
- Altman Z (18.25)25/25
- Current ratio (3.02)25/25
- Interest coverage (108.0x)25/25
- Net cash / debt (Net cash)25/25
- Quality82/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.55)25/25
- FCF conversion (77%)15/25
- Margin stability (σ 5.0%)20/25
- Moat81/100 · Strong
- ROIC >12% years (10/10 yrs)25/25
- Median gross margin (35.1%)13/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 9.4%)18/25
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. Show more
West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Headquarters: EXTON, PA · Employees: 10,800 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
27EP/E (TTM)47.8xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 25.2x–66.7x · 72nd pct
P/FCF63.0xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield1.6%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.8%–2.5% · 49th pct
P/S (TTM)8.12xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 4.8x–13.7x · 52nd pct
EV/EBIT38.9xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 19.5x–57.0x · 64th pct
EV/Sales8.2xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E38.2xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio8.51xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.05D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.23%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio11.1%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
80AROIC20.8%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE17.8%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA13.6%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin17.0%A
Grade A: HighNet Income / Revenue
Operating Margin20.5%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin36.8%C
Grade C: AverageGross Profit / Revenue
FCF Margin13.1%C
Grade C: AverageFCF / Revenue
True FCF Margin12.2%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
26ERevenue CAGR2.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-7.1%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-5.9%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth25.2%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-7.2%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income5.8%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
100A+Altman Z-Score18.25A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.02xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.12xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage108.0xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.06xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt3.90xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
82APiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.55A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion77.3%C
Grade C: AverageFCF / Net Income
Margin Stability5.0%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue6.8%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.80xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
HAUGEN JANET BRUTSCHEA Filed | HAUGEN JANET BRUTSCHEA | Grant / award | +44 | |
Favorite Annette F Filed | Favorite Annette F | Option exercise | -2524 | |
Favorite Annette F Filed | Favorite Annette F | SellOpen market sale | -2524 | |
Favorite Annette F Filed | Favorite Annette F | Option exercise | +2.5K | |
Favorite Annette F Filed | Favorite Annette F | Option exercise | -2500 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Favorite Annette F Filed | Favorite Annette F | SellOpen market sale | -2500 | |
Favorite Annette F Filed | Favorite Annette F | Option exercise | +2.5K | |
Favorite Annette F Filed | Favorite Annette F | Option exercise | -2500 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
81AROIC >12% Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)35.1%C
Grade C: ModerateMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor9.4%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$8.03
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$6.19
Cash & short-term investments per share (Finnhub)
Book Value / Share$42.47
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$202.80M
Total debt obligations (short + long term)
Cash & Equiv.$791.30M
Cash and short-term investments
Net Debt$-588.50MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$3.18B
Shareholders' equity (book value)
Asset / Liability3.90xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$27.03B
Current Market Capitalization
Beta1.15B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: West Pharmaceutical Services, Inc. (WST)
West Pharmaceutical Services, Inc. meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 18.25 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.55 suggests a low likelihood of earnings manipulation.
- Company is effectively debt-free after netting cash.
- At a valuation score of 27/100, WST trades at a premium to its historical multiples (P/E 47.8).
See how WST ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all WST moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 5 | After-hours | 376.76 | +3.23% | 2.00 |
Frequently Asked Questions about WST
What is the current West Pharmaceutical Services, Inc. (WST) stock price?
WST is trading at $384.02 in after-hours trading, up 0.26% on the session. PreMarketPrice tracks WST pre-market, intraday and after-hours prices.
Is WST stock a buy right now?
PreMarketPrice's quantitative model rates West Pharmaceutical Services, Inc.'s financial health at 100/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is WST stock overvalued?
West Pharmaceutical Services, Inc. trades at a trailing P/E of 47.8 and our valuation score rates it 27/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does West Pharmaceutical Services, Inc. report earnings?
No confirmed earnings date is currently scheduled for WST. The Earnings section lists recent reports and updates as dates are announced.
What sector does West Pharmaceutical Services, Inc. operate in?
West Pharmaceutical Services, Inc. operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does West Pharmaceutical Services, Inc. do?
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries.
About West Pharmaceutical Services, Inc. (WST) Stock
West Pharmaceutical Services, Inc. (WST) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, West Pharmaceutical Services, Inc. is trading at $384.02, up 0.26% on the day with a market capitalization of $27.0 billion. The financial health score for WST is 100/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for WST stock.
WST Stock Analysis & Key Metrics
On PreMarketPrice, you can track West Pharmaceutical Services, Inc. (WST) across multiple dimensions:
- Pre-market price & movement: Real-time WST stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for WST with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for West Pharmaceutical Services, Inc. across multiple reporting periods.
- Financial health score: A composite score of 100/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for WST.
- Sector peers: Compare WST against 6 other healthcare stocks on key financial metrics.
Is WST a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate West Pharmaceutical Services, Inc. (WST) as an investment. The financial health score of 100/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.West Pharmaceutical Services, Inc. (WST) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.